Adjuvant systemic therapy for male breast carcinoma.

@article{Giordano2005AdjuvantST,
  title={Adjuvant systemic therapy for male breast carcinoma.},
  author={Sharon Hermes Giordano and George H. Perkins and Kristine R Broglio and Sherry G Garcia and Lavinia P. Middleton and Aman U. Buzdar and Gabriel N Hortobagyi},
  journal={Cancer},
  year={2005},
  volume={104 11},
  pages={2359-64}
}
BACKGROUND In the current study, the authors describe the M. D. Anderson experience with adjuvant systemic therapy in male breast carcinoma patients. METHODS A total of 156 men with a diagnosis of breast carcinoma registered and were treated at the M. D. Anderson Cancer Center between 1944 and 2001. One hundred thirty-five men had nonmetastatic breast carcinoma at diagnosis and were included in this analysis. Patients' charts were retrospectively reviewed to obtain details of patient… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
Tumors were estrogen receptor - positive in 85% of cases and progesterone receptor - positive in 71% .
Tumors were estrogen receptor - positive in 85% of cases and progesterone receptor - positive in 71% .
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
The 5-year and 10-year overall survival rates were 86% and 75% , respectively , for men with lymph node - negative disease and 70% and 43% , respectively , for men with lymph node - positive disease .
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
Approximately 81% received anthracycline - based regimens ; 9% received additional taxanes ; and 16% were treated with cyclophosphamide , methotrexate , and 5-fluorouracil ( CMF ) .
Chemotherapy was administered to 32 men ( 84% with adjuvant chemotherapy , 6% with neoadjuvant chemotherapy , and 9% with both ) .
Chemotherapy was administered to 32 men ( 84% with adjuvant chemotherapy , 6% with neoadjuvant chemotherapy , and 9% with both ) .
Lymph Node TissueAnatomic structure is physical part oflymph nodes
The 5-year and 10-year overall survival rates were 86% and 75% , respectively , for men with lymph node - negative disease and 70% and 43% , respectively , for men with lymph node - positive disease .
The 5-year and 10-year overall survival rates were 86% and 75% , respectively , for men with lymph node - negative disease and 70% and 43% , respectively , for men with lymph node - positive disease .
All Topics